Central tolerance, also known as negative selection, is the process of eliminating any developing T or B lymphocytes that are reactive to self. Through elimination of autoreactive lymphocytes, tolerance ensures that the immune system does not attack self peptides. Lymphocyte maturation (and central tolerance) occurs in primary lymphoid organs such as the bone marrow and the thymus. In mammals, B cells mature in the bone marrow and T cells mature in the thymus.
Burnet and Medawar won the Nobel Prize in 1960 for their work in explaining how immune tolerance worked. (See the ACR Institute’s Nobel Prize file)
Given the lack of perfection in evolutionary biology, there usually are back-up mechanisms to ensure the continuation of reproductive Life. As a consequence, peripheral tolerance exists as a secondary mechanism to ensure that T and B cells are not self-reactive once they leave primary lymphoid organs. Peripheral tolerance is distinct from central tolerance in that it occurs once developing immune cells exit primary lymphoid organs (the thymus and bone-marrow), prior to their export into the periphery.
Central tolerance is essential to proper immune cell functioning because it helps ensure that mature B cells and T cells do not recognize self antigens as foreign microbes. More specifically, central tolerance is necessary because T cell receptors (TCRs) and B cell receptors (BCRs) are made by cells through random somatic rearrangement. This process, known as V(D)J recombination, is important because it increases the receptor diversity which increases the likelihood that B cells and T cells will have receptors for novel antigens. Junctional diversity occurs during recombination and serves to further increase the diversity of BCRs and TCRs. The production of random TCRs and BCRs is an important method of defense against microbes due to their high mutation rate. This process also plays an important role in promoting the survival of a species because there will be a variety of receptor rearrangement within a species meaning that there is a very high chance of at least one member of the species having receptors for a novel antigen.
While the process of somatic recombination is essential to a successful immune defense, it can lead to autoreactivity. For example, lack of functional RAG1/2, enzymes necessary for somatic recombination, has been linked to development of immune cytopenias in which antibodies are produced against the patient’s blood cells. Due to the nature of a random receptor recombination, there will be some BCRs and TCRs produced that recognize self antigens as foreign. This is problematic since these B and T cells would, if activated, mount an immune system attack against self if not killed or inactivated by central tolerance mechanisms. Therefore, without central tolerance, the immune system could attack self, which is not sustainable and could result in an autoimmune disorder.
The end result of tolerance is a population of lymphocytes that are not reactive to self-antigens, but may be able to recognize foreign, non-self antigens depending on the randomly arranged receptor. Importantly, lymphocytes can only develop tolerance towards antigens that are present in the bone marrow (for B cells) and thymus (for T cells).
This figure depicts the process of B cell selection in the bone marrow.
Immature B cells in the bone marrow undergo negative selection when they bind self peptides. Properly functioning B cell receptors recognize non-self antigen or pathogen associated molecular proteins (PAMPs). Main outcomes of autoreactivity of BCRs  Apoptosis (clonal deletion) Receptor editing: the self-reactive B cell changes specificity by rearranging genes and develops a new BCR that does not respond to self. This process gives the B cell a chance for editing the BCR before it is signaled to apoptose or become anergic. Induction of anergy (a state of non-reactivity)
Steps of T Cell Tolerance
T cell central tolerance occurs in the thymus. T cells undergo positive and negative selection. T cell receptors must have the ability to recognize self major histocompatibility complex (MHC) molecules with bound non-self peptide. Steps of T cell tolerance  During positive selection, T cells are checked for their ability to bind peptide-MHC complexes with affinity. If the T cell cannot bind the MHC class I or MHC class II complex, it does not receive survival signals, so it dies via apoptosis. T cell receptors with sufficient affinity for peptide-MHC complexes are selected for survival. Depending on whether the T cell binds MHC I or II, it will become a CD8+ or CD4+ T cell, respectively. Positive selection occurs in the thymic cortex with the help of thymic epithelial cells that contain surface MHC I and MHC II molecules.
Regulatory T cells are another type of T cell that mature in the thymus. Selection of T reg cells occurs in the thymic medulla and is accompanied by the transcription of Foxp3. T reg cells are important for regulating autoimmunity by suppressing the immune system when it should not be active.
Genetic defects in central tolerance can lead to autoimmunity.
Autoimmune Polyendocrinopathy Syndrome Type I is caused by mutations in the human gene AIRE. This leads to a lack of expression of peripheral antigens in the thymus, and hence a lack of negative selection towards key peripheral proteins such as insulin. Multiple autoimmune symptoms result. The first use of central tolerance was by Ray Owen in 1945 when he noticed that dizygotic twin cattle did not produce antibodies when one of the twins was injected with the others blood. His findings were confirmed by later experiments by Hasek and Billingham. The results were explained by Buret’s clonal selection hypothesis. As noted Burnet and Medawar won the Nobel Prize in 1960 for their work in explaining how immune tolerance worked.
Text under investigation & construction
- Owen JA, Punt J, Stranford SA, Jones PP, Kuby J (2013). Kuby immunology (7th ed.). New York: W.H. Freeman. ISBN 978-1-4292-1919-8. OCLC 820117219.
- Romagnani S (2006). “Immunological tolerance and autoimmunity”. Internal and Emergency Medicine. 1 (3): 187–96. PMID 17120464.
- Janeway C (2011). Immunobiology 5: The Immune System in Health and Disease (5th ed.). New York: Garland. ISBN 978-0-8153-3642-6. OCLC 45708106.
- Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, McManus MP, Pulsipher MA, Yandell M, Bohnsack JF, Jorde LB, Notarangelo LD, Walter JE (March 2014). “Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations”. The Journal of Allergy and Clinical Immunology. 133 (3): 880–2.e10. doi:10.1016/j.jaci.2013.11.038. PMC 4107635. PMID 24472623.
- Sprent J, Kishimoto H (May 2001). “The thymus and central tolerance”. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 356 (1409): 609–16. doi:10.1098/rstb.2001.0846. PMC 1088448. PMID 11375064.
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (May 2006). “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells”. Nature. 441 (7090): 235–8. doi:10.1038/nature04753. PMID 16648838.
- Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D (November 2002). “Projection of an immunological self shadow within the thymus by the aire protein”. Science. 298(5597): 1395–401. doi:10.1126/science.1075958. PMID 12376594.
- Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC (April 2003). “Aire regulates negative selection of organ-specific T cells”. Nature Immunology. 4 (4): 350–4. doi:10.1038/ni906. PMID 12612579.
- Schwartz RH (April 2012). “Historical overview of immunological tolerance”. Cold Spring Harbor Perspectives in Biology. 4 (4): a006908. doi:10.1101/cshperspect.a006908. PMC 3312674. PMID 22395097.
- Liston A (January 2011). “Immunological tolerance 50 years after the Burnet Nobel Prize”. Immunology and Cell Biology. 89 (1): 14–5. doi:10.1038/icb.2010.138. PMID 21209621.
- Silverstein AM (March 2016). “The curious case of the 1960 Nobel Prize to Burnet and Medawar”. Immunology. 147 (3): 269–74. doi:10.1111/imm.12558. PMC 4754613. PMID 26790994.